Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-25-080957
Filing Date
2025-08-20
Accepted
2025-08-20 16:58:10
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 7343
2 EXHIBIT A tm2524012d1_ex99-a.htm EX-99.A 28995
  Complete submission text file 0001104659-25-080957.txt   38091
Mailing Address 2450 HOLCOMBE BLVD TMC PARTNERS OFFICE 1.311 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD TMC PARTNERS OFFICE 1.311 HOUSTON TX 77021 (713) 400-6400
Marker Therapeutics, Inc. (Subject) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-58217 | Film No.: 251237518
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 33 5TH AVENUE NEW BRIGHTON MN 55112
Business Address
Wilson John Robert (Filed by) CIK: 0001755569 (see all company filings)

Type: SCHEDULE 13D/A